Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (S-1 adjuvant)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02564367
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : April 29, 2021
Sponsor:
Collaborators:
Nordic Pharma SAS
Taiho Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
AIO-Studien-gGmbH

Brief Summary:

Multicenter trial in Germany:

Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction with the aim to show the feasibility and tolerability of adjuvant S-1 treatment in Caucasian patients and to determine the recommended dose for the treatment regimen.


Condition or disease Intervention/treatment Phase
Adenocarcinoma,Stomach Adenocarcinoma, Esophagogastric Junction Drug: S-1 Phase 1 Phase 2

Detailed Description:

Patients will be enrolled in one cohorts.

Cohort 1 consists of 30 patients who receive S-1 twice daily for 18 cycles (D1-14 q 3 wks).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase I/II Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction
Actual Study Start Date : October 6, 2015
Actual Primary Completion Date : March 1, 2019
Actual Study Completion Date : March 6, 2020

Arm Intervention/treatment
Experimental: Treatment

First Cohort 1:

(n = 30 patients) 18 cycles S-1

Drug: S-1

18 cycles S-1, orally administered twice daily D1-14, q 3 wks

S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks

Other Name: Teysuno




Primary Outcome Measures :
  1. number of patients with discontinuation of S-1 due to intolerable adverse reactions [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. One-year relapse-free survival rate [ Time Frame: 12 months ]
    Mo local relapse or distant metastases within one year after start of adjuvant treatment

  2. Relapse-free survival [ Time Frame: 2 years ]
    relapse-free survival until end of study

  3. Quality of life [ Time Frame: 12 months ]
    European Organisation for Research and Treatment of Cancer (EORTC) C30 questionnaires

  4. One-year survival rate [ Time Frame: 1 years ]
  5. Overall survival [ Time Frame: 2 years ]

Other Outcome Measures:
  1. plasma concentration of Tegafur (FT) [ Time Frame: 12 months ]
    To evaluate the pharmacokinetics of FT

  2. plasma concentration of 5-Fluorouracil (5-FU) [ Time Frame: 12 months ]
    To evaluate the pharmacokinetics of 5-FU

  3. plasma concentration of Gimeracil (CDHP) [ Time Frame: 12 months ]
    To evaluate the pharmacokinetics of CDHP



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient signed and dated informed consent before the start of any specific protocol procedures
  2. Adult Caucasian patients ≥ 18 years of age
  3. Histologically confirmed diagnosis of adenocarcinoma of the stomach and esophagogastric (EG) junction classified as uT2/uT3/uT4, any N category, M0 or any uT, N+, M0 patient (for patients having received neoadjuvant chemotherapy) or pT2/pT3/pT4, any N category, M0 or any pT, N+, M0 (for patients having received primary surgery) according to Union international contre le cancer (UICC) TNM edition 7.
  4. R0-resection after neoadjuvant treatment. However, patients can also be included if neoadjuvant treatment could not be performed due to medical indication of primary surgery (perforation, bleeding etc.) or was not performed due to understaging.
  5. D2 lymph node dissection performed
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  7. Consent to translational research being performed on tumor tissue of the primary tumor that had been removed during the resection surgery. Translational research will be performed only upon completion of routine histological and pathological evaluations of the tumor
  8. Females of childbearing potential (FCBP) must have a negative pregnancy test within 7 days of the first application of study treatment and must agree to use effective contraceptive birth control measures (Pearl Index < 1) during the course of the trial and for at least 6 months after last application of S-1.

    Females of childbearing potential (FCBPs) should be included after a confirmed menstrual period (only if applicable, i.e. still having menses) and must have a negative highly sensitive pregnancy test within 7 days prior to the first application of study treatment and must agree to use highly effective contraceptive birth control measures (Pearl Index < 1) during the course of the trial and for at least 6 months after last application of S-1.

    Such highly effective birth control methods include:

    • oral, intravaginal, or transdermal combined hormonal contraception associated with inhibition of ovulation
    • oral, injectable, or implantable progesterone-only hormonal contraception associated with inhibition of ovulation
    • intrauterine device
    • intrauterine hormone-releasing system
    • bilateral tubal occlusion
    • commitment to complete abstinence from heterosexual contact

    A female subject following menarche is considered to be of childbearing potential unless she is naturally amenorrhoeic for ≥ 1 year without an alternative medical reason, or unless she is permanently sterile (permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy).

  9. Males must agree not to father a child during the course of the trial and for at least 6 months after last administration of S-1 and must agree to use condoms during the course of the trial and for at least 6 months after last administration of S-1 in case of sexual intercourse with FCBP or pregnant female.
  10. Patient must be able to take medication orally within eight weeks after surgery at the start of S-1.
  11. Normal cardiac function demonstrated by Electrocardiogram (ECG) and echocardiogram (LVEF ≥ 55%)
  12. Adequate bone marrow, hepatic and renal function defined as

    • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
    • Haemoglobin ≥ 9 g/dL
    • Platelets ≥ 100 x 10^9/L
    • Albumin ≥ 2.5 g/dL
    • Total bilirubin ≤ 2 mg/dL
    • GOT/AST and GPT/ALT ≤ 3 x Upper normal limit (ULN)
    • Calculated creatinine clearance according to MDRD equation ≥ 50 mL/min
  13. Patient's legal capacity to consent to study participation

Exclusion Criteria:

  1. Metastatic disease (exclusion of metastatic disease by a postoperative CT or MRI scan of thorax and abdomen within 3 weeks prior to start of adjuvant therapy)
  2. Polyneuropathy > grade 1 (NCI CTCAE version 4.0)
  3. Evidence of ascites or liver cirrhosis
  4. Patient is pregnant or breast-feeding
  5. Patient underwent a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment, or there is an anticipated need for major surgical procedure during the course of the study.
  6. Heart failure ≥ NYHA functional classification system grade 2
  7. Myocardial infarction, unstable angina, cardiac angioplasty or stenting procedure within the last 6 months.
  8. Medical history of pulmonary fibrosis or interstitial lung disease (ILD)
  9. Active or uncontrolled bacterial, viral, or fungal infection that requires systemic treatment
  10. Known HIV-, HBV-, and HCV-infection
  11. Concurrent disease or condition that would make the patient inappropriate for study participation or would interfere with the patient's safety.
  12. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  13. Any cancer therapy (chemotherapy, radiation therapy, biologic therapy, immunotherapy, or hormonal therapy) after resection surgery or requirement for concurrent cancer treatment during study treatment with S-1.
  14. Participation in another clinical trial or treatment with an investigational drug after surgery and during study treatment with S-1.
  15. Known immediate or delayed hypersensitivity to any of the active substances of S-1 (tegafur, gimeracil, and oteracil) or to any of the excipients or to drugs chemically related to S-1 (e.g. 5-fluorouracil)
  16. History of severe and unexpected reactions to fluoropyrimidine therapy
  17. Known dihydropyrimidine dehydrogenase (DPD) deficiency
  18. Treatment with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine within 4 weeks before start of study drug or during study treatment
  19. Previous or concurrent malignant tumor disease other than underlying tumor disease with the exception of cervical cancer in situ, adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder tumors (Ta, Tis, and T1) or any curatively treated tumors > 5 years prior to enrolment
  20. Known alcohol abuse or drug addiction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564367


Locations
Layout table for location information
Germany
Klinikum der Universität München, Campus Großhadern
München, Bayern, Germany
Sponsors and Collaborators
AIO-Studien-gGmbH
Nordic Pharma SAS
Taiho Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Volker Heinemann, Prof. Dr. Klinikum der Universität München, Campus Großhadern
Layout table for additonal information
Responsible Party: AIO-Studien-gGmbH
ClinicalTrials.gov Identifier: NCT02564367    
Other Study ID Numbers: GMBH-STO-0114
2014-004116-11 ( EudraCT Number )
First Posted: September 30, 2015    Key Record Dates
Last Update Posted: April 29, 2021
Last Verified: April 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms